DNA binding sites for putative methylation boundaries in the unmethylated region of the BRCA1 promoter

International Journal of Cancer. Journal International Du Cancer
Darci T ButcherDavid I Rodenhiser

Abstract

Changes in DNA methylation patterns are frequently observed in human cancers and are associated with a decrease in tumor suppressor gene expression. Hypermethylation of the BRCA1 promoter has been reported in a portion of sporadic breast tumours that correspond to a reduction in BRCA1 transcription and expression. Questions remain concerning the maintenance of methylation free zones in promoter regions of tumor suppressor genes in normal tissues. Sodium bisulfite based analysis of the BRCA1 promoter defines a methylation free zone in normal breast tissue that starts 650 bp upstream of the transcription start site and extends for 1.4 kb through most of the BRCA1 CpG island. We provide data implicating 2 proteins, Sp1 and CTCF, in the maintenance of this methylation-free zone. Both of these proteins have been shown to function as methylation boundaries in other genes. Four Sp1 sites have been identified in the BRCA1 promoter by gel shift assays. In vivo binding of Sp1 has been confirmed at 2 of these sites in the BRCA1 promoter and at 2 CTCF sites that flank the unmethylated region. Our data suggest that these DNA binding sites for Sp1 and CTCF may act as boundary elements that are important in maintaining genomic integrity by de...Continue Reading

References

Jan 1, 1994·Human Molecular Genetics·P W Laird, R Jaenisch
Oct 11, 1994·Proceedings of the National Academy of Sciences of the United States of America·J G HermanW M Linehan
Aug 11, 1994·Nucleic Acids Research·S J ClarkM Frommer
Jan 1, 1995·Human Molecular Genetics·C I Szabo, M C King
Jun 18, 1997·Biochemical and Biophysical Research Communications·M Schroeder, M J Mass
Jul 1, 1997·American Journal of Human Genetics·D ManciniD Rodenhiser
Aug 11, 1997·Gene·S J ClarkP L Molloy
Jan 1, 1997·Annual Review of Genetics·E HeardP Avner
Apr 29, 1998·Disease Markers·J W Paterson
Jan 9, 1999·The Journal of Biological Chemistry·A R BlackJ C Azizkhan
Jan 14, 1999·Genes & Development·C P Walsh, T H Bestor
Mar 13, 1999·International Journal of Cancer. Journal International Du Cancer·P G RioD J Bernard-Gallon
Jun 16, 1999·Nature Genetics·Z SiegfriedH Cedar
Oct 27, 1999·Proceedings of the National Academy of Sciences of the United States of America·G J NuovoJ G Herman
Dec 10, 1999·Proceedings of the National Academy of Sciences of the United States of America·J M GreallyR D Nicholls
Apr 6, 2000·Journal of the National Cancer Institute·M EstellerJ G Herman
Aug 5, 2000·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·C X Deng, S G Brodie
Aug 30, 2001·Trends in Genetics : TIG·R OhlssonV Lobanenkov
Sep 6, 2001·Oncogene·D N DiNardoD I Rodenhiser
Apr 5, 2002·Nature·Ina RheeBert Vogelstein
May 17, 2002·The Journal of Biological Chemistry·Normand BeaulieuA Robert MacLeod
Aug 3, 2002·Oncogene·Melanie Ehrlich
Dec 4, 2002·Genes, Chromosomes & Cancer·Yasuyuki MiyakuraHideo Nagai
Mar 26, 2003·The American Journal of Pathology·Carolyn BariolRobyn Ward
Apr 19, 2003·Science·Amir EdenRudolf Jaenisch
Apr 19, 2003·Science·François GaudetRudolf Jaenisch

❮ Previous
Next ❯

Citations

Nov 6, 2008·Cellular and Molecular Life Sciences : CMLS·J K KimS Pradhan
May 26, 2009·Breast Cancer Research and Treatment·Jinhua XuOlufunmilayo I Olopade
Jul 30, 2005·Nucleic Acids Research·Emilie AuriolRobert Dante
Jan 22, 2011·Nucleic Acids Research·Narendra Pratap SinghRakesh K Mishra
Sep 8, 2012·Genome Research·Hao WangJohn A Stamatoyannopoulos
Sep 4, 2008·Molecular and Cellular Biology·Phuongmai NguyenDavid Gius
Jan 11, 2007·Molecular and Cellular Biology·Igor ChernukhinElena Klenova
Nov 26, 2010·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Michèle Amouyal
Aug 19, 2011·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Félix Recillas-TargaErnesto Soto-Reyes
Oct 17, 2008·Cancer Research·Petr NovakBernard W Futscher
Nov 17, 2009·BMC Genetics·Jeffrey N BryanCharles W Caldwell
Jun 15, 2011·BMC Cancer·Mercedes Dávalos-SalasFélix Recillas-Targa
Jan 27, 2012·BMC Cancer·Ernesto Soto-ReyesLuis A Herrera
May 27, 2009·PLoS Biology·Jinglan LiuIan D Krantz
Jan 7, 2014·PloS One·Renáta TóthZoltán Zádori
Aug 9, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Chu-Yi WuMing-Ta Hsu
Oct 31, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Darci T Butcher, David I Rodenhiser
Mar 27, 2009·The EMBO Journal·Tsuyoshi MishiroMitsuyoshi Nakao
Nov 21, 2009·The Journal of Pathology·Elliott Lever, Denise Sheer
Aug 11, 2015·Cell Reports·Matthew T MauranoJohn A Stamatoyannopoulos
Sep 5, 2006·Molecular Cell·Ko IshiharaMitsuyoshi Nakao
Jan 5, 2018·Oncotarget·Na DengYuan Yuan
Sep 23, 2006·Journal of Cellular and Molecular Medicine·Felix Recillas-TargaLuis Benítez-Bribiesca
May 26, 2017·Journal of Gynecologic Oncology·Yaw Wen HsuHung Cheng Lai
Dec 11, 2007·The Journal of Biological Chemistry·Bekim SadikovicDavid I Rodenhiser
Mar 17, 2007·Cancer Research·Inti A De La Rosa-VelázquezFélix Recillas-Targa
Oct 30, 2020·Cancers·Magdalena GebertRafał Bartoszewski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.